{"name":"RHEACELL GmbH & Co. KG","slug":"rheacell-gmbh-co-kg","ticker":"","exchange":"","domain":"","description":"RHEACELL GmbH & Co. KG is a biotechnology company focused on developing innovative cell therapies for various medical conditions. The company has a pipeline of 8 drug candidates, with several in early clinical stages, including allo-APZ2-OTS in Phase 3 and allo-APZ2-EB and allo-APZ2-DFU in Phase 1.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"allo-APZ2-CVU","genericName":"allo-APZ2-CVU","slug":"allo-apz2-cvu","indication":"Atrial fibrillation for stroke prevention","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"allo-APZ2-OTS","genericName":"allo-APZ2-OTS","slug":"allo-apz2-ots","indication":"Multiple sclerosis","status":"phase_3"}]}],"pipeline":[{"name":"allo-APZ2-CVU","genericName":"allo-APZ2-CVU","slug":"allo-apz2-cvu","phase":"phase_3","mechanism":"Allo-APZ2-CVU is a small molecule that targets the CVU receptor.","indications":["Atrial fibrillation for stroke prevention"],"catalyst":""},{"name":"allo-APZ2-OTS","genericName":"allo-APZ2-OTS","slug":"allo-apz2-ots","phase":"phase_3","mechanism":"Allo-APZ2-OTS is a small molecule that targets the sphingosine-1-phosphate receptor 1 (S1PR1).","indications":["Multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPTGFlNmx0T2ZSSXpIclNPMjdnLVUxX3JkUHB1REtfbzdhcktLbkI5X3pVT0NWYXFKSGNFT1g5alRCNTlXOUs4R040V28tTXZrNXNrVzROYlFTTUtsMDQweldLYnY3cEZ2eU16ZjdkWnJmcENhaURsVTZ0MlJoYWpWd3lMdlMtR0thY3BpZEVaV3JWdFpWSm81ZjhUdnZSaEhyTDFDdjdzNF9pMC1IcmlZQjcwcWJxRTlsY2M0NHE1TUlxVDNPMDZ3RklpcjRCMHNRVnF5VzQzR3BUVWNyZF9JWUhyc210TzR6YzZjakp6cE9vRzIxOVRNWlVR?oc=5","date":"2025-05-22","type":"regulatory","source":"PR Newswire","summary":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight - PR Newswire","headline":"ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight","sentiment":"positive"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}